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SUmmArY – no definite consensus exists currently regarding the appropriate age at which to 
start cervical cancer screening. we analyzed the effectiveness of age in abnormal histology outcomes 
in women aged 20-29. data on women aged 20-29 having undergone opportunistic cervical cancer 
screening with cytology during the 2014-2019 period were retrospectively reviewed. Based on cytol-
ogy outcomes, human papillomavirus test results (if present), age and clinical decision, patients under-
went either colposcopy or observation. The effects of age and other epidemiologic factors on histo-
logic diagnoses of cervical intraepithelial neoplasia (Cin) or cancer [Cin (+)] were analyzed in uni-
variate and binomial logistic regression analyses. Among 1649 women, Cin (+) lesions were observed 
in 61 (3.7%) women. The occurrence of Cin (+) lesions increased 1.149 times each year; thus, women 
aged 25-29 were more likely to have Cin (+) than those aged 20-24 (4.4% vs. 2.1%; p=0.019). A 
significant determinant of Cin (+) was the increase in age, i.e. women aged 20-29. Accordingly, con-
sidering age is crucial for the diagnosis of Cin (+) in cancer screening.
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Introduction
Cervical cancer is the fourth most commonly diag-
nosed and the fourth leading cause of death in fe-
males1. it is estimated that almost 570,000 new cases 
of cervical cancer and 311,000 associated deaths 
among women occur worldwide each year1. in Turkey, 
cervical cancer is the 9th most common cancer, with an 
estimated incidence rate of 4.3/100,0002. it is under-
stood that regular cervical cancer screening promotes 
early detection of cervical premalignant lesions and 
decreases mortality rate from cervical cancer. however, 
there is no consensus regarding the starting age for 
cervical cancer screening worldwide. Starting screen-
ing at 20 years of age may have little effect on detect-
ing cervical cancer but may carry potential harm due 
to the treatment of high-grade cervical lesions that 
may regress with time, leading to adverse pregnancy 
outcomes such as preterm birth and low birth weight3. 
On the other hand, starting cervical cancer screening 
at the age of 30 years may lead to missing cervical in-
traepithelial neoplasia (Cin) lesions that have the po-
tential risk of developing into cervical cancer.
The age for starting cervical cancer screening is be-
tween 20-30 in most countries globally. Turkey boasts 
a national cervical cancer screening program involving 
human papillomavirus (hPv) testing starting at the 
age of 30. for younger ages, opportunistic screening is 
available. Cervical cancer screening is individual-based 
and performed depending on the decisions of the cli-
nicians and patients involved. There are limited data on 
the prevalence rates of Cin and cervical cancer in 
women aged 20-29 in Turkey. we therefore sought to 
analyze the prevalence of abnormal screening results 
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among women aged 20-29 years in the Akdeniz Uni-
versity department of Obstetrics and gynecology to 
elucidate the prevalence of abnormal cytologic results 
not screened for in the national program. we also 
aimed to gather scientific evidence for the implemen-
tation of cervical cancer screening among women aged 
20-29 by analyzing the effects of age and possible epi-
demiologic cofactors on developing colposcopy diag-
nosed abnormal histology outcomes.
Patients and Methods
After approval of the study was granted by the local 
institutional ethics Committee (approval no. 818), we 
retrospectively investigated women aged 20-29 (<30) 
having undergone cervical cancer screening with cy-
tology between 2014 and 2019. The study was per-
formed in accordance with the ethical standards de-
scribed in the appropriate version of the 1975 declara-
tion of helsinki, as revised in 2000.
Patients with a known history of Cin or gyneco-
logic cancer, and those that were pregnant were ex-
cluded from this study. if a woman underwent two or 
more cytologic investigations during the study period, 
the age at which abnormal cytology results were ob-
served was taken into account. Conversely, if all cytol-
ogy findings were normal, then the mean age among 
all the times the patient was examined was calculated 
and taken into account on data analysis. Only patients 
with satisfactory cytology outcomes were included in 
the analysis. if a patient had normal cytology but an 
absent/insufficient endocervical/transformation zone, 
she was excluded from this study.
demographic data, marital status, past obstetric 
and gynecologic history, gravidity, parity, number of 
abortions, current use of a contraceptive method, 
smoking habit, cytology, hPv test results (if available), 
and cervical biopsy results were collected. Considering 
the need for colposcopy according to the American 
Society for Colposcopy and Cervical Pathology (AS-
CCP) guidelines, women who had not undergone col-
poscopy were excluded from statistical analysis per-
formed for the association of age and other character-
istics with Cin lesions.
liquid-based cytology was used in all women. 
normal cytology was defined as negative for intraepi-
thelial lesion or malignancy. Cytology results were re-
ported according to the Bethesda classification, as fol-
lows: abnormal findings included atypical squamous 
cells of undetermined significance (ASC-US); atypical 
squamous cells suspicious for high-grade squamous 
intraepithelial lesions (ASC-h); low-grade squamous 
intraepithelial lesions (lSil); high-grade squamous 
intraepithelial lesions (hSil); atypical glandular cells 
(AgC); adenocarcinoma in situ; and invasive cancer.
The management of abnormal cytology results was 
performed according to the ASCCP guidelines. Based 
on cytology outcomes, hPv test results (if present), 
patient age and clinical decision, patients underwent 
either colposcopy or observation with repeat screening 
testing. According to this management protocol, 
women aged 21-24 with ASC-US or l-Sil cytology 
were those who underwent colposcopy (e.g., if a pa-
tient had postcoital bleeding, obvious cervical lesions, 
and condyloma accuminata, she underwent colposco-
py); otherwise, the patient underwent repeat cytology 
at 12 months later. At 12 months, if the patient had 
ASC-h, AgC, or hSil, colposcopy was performed, 
but if the findings were negative, ASC-US or lSil 
without any clinical suspicion, then the patient under-
went repeat cytology again 12 months later, and so 
forth. if the patient had ASC-US with negative hPv 
test results, she was allocated to the Cin (-) group. The 
women aged 25 or older with ASC-US cytology with-
out any clinical suspicion underwent hPv testing (if 
available during the study period); otherwise, repeat 
cytology was planned at one year and colposcopy was 
performed according to cytology results at one year. 
The women aged 25 or older with lSil cytology 
without any clinical suspicion underwent colposcopy 
alone or colposcopy in conjunction either with hPv 
testing or follow-up cytology at one year. women of all 
ages with ASC-h or hSil findings underwent col-
poscopy. Standard colposcopic techniques were used 
on colposcopy, including observing the cervix after the 
application of 3% acetic acid and taking biopsies from 
all abnormal areas.
The prevalence of cytology findings was analyzed 
in the population of women in whom cytology was 
performed. Colposcopic biopsies were reported as nor-
mal (no Cin lesions), Cin grade 1, Cin grade 2, Cin 
grade 3, and invasive cancer. Cin grade 1 lesions were 
also defined as histology-proven lSil, while Cin 
grades 2 and 3 lesions were defined as histology-prov-
en hSil.
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Statistical method
Statistical Package for the Social Sciences version 
23.0 for windows software program (iBm Corp., Ar-
monk, nY, USA) was used for statistical analyses. fre-
quencies of normal and abnormal cytology findings 
and hPv were calculated using descriptive statistics in 
the whole study population. The occurrence of histo-
logically diagnosed Cin lesions or cancer was defined 
as the response variable [Cin (+)]. Continuous vari-
ables included age, gravidity, and parity. These param-
eters were evaluated by visual (e.g., histograms and 
probability plots) and analytical (Kolmogorov-
Smirnov/Shapiro-wilk test) methods to assess wheth-
er they were normally distributed or not. Abnormally 
distributed parameters were expressed as medians and 
percentiles, whereas normally distributed parameters 
were expressed as means. Categorical variables (e.g., 
any contraceptive method, smoking habit, age range 
21-24 or 25-29) were expressed as numbers and fre-
quencies. The χ2-test was used to evaluate the relation-
ship of those categorical variables with the occurrence 
of Cin (+). women with abnormal cytology who were 
neither followed-up with nor received colposcopy in 
the Akdeniz University department of Obstetrics and 
gynecology were not included in statistical analysis of 
Cin (+) occurrence.
A p-value of 0.25 on univariate analysis was con-
sidered as a restrictive alpha level. Therefore, parame-
ters with p-values <0.25 on univariate analysis were 
included in the binomial logistic regression analysis. 
The forward likelihood ratio method was used and p-
values <0.05 were defined as statistically significant in 
binomial logistic regression analysis.
Results
A total of 1756 women screened by cytology were 
evaluated in this study. Thirteen women with Cin diag-
nosis, nine women whose epidemiological characteris-
tics could not be determined, three women with ovarian 
cancer diagnosis, two women with cervical cancer diag-
nosis, and one woman having undergone hysterectomy 
for benign reasons were excluded from the study. Thus, 
1728 women with smear results were evaluated.
On cytologic examinations of 1728 women, 1521 
(88.0%) women were found to be normal, 130 (7.5%) 
women were ASCUS, 55 (3.2%) women were lSil, 
14 (0.8%) women were ASCh, five (0.3%) women 
were hSil, and three (0.2%) women were AgC. 
hPv was tested in 382 women and 95 (24.9%) of 
these were hPv (+).
Seventy-nine women with abnormal cytology but 
who were neither followed-up with nor received col-
poscopy in the Akdeniz University department of 
Obstetrics and gynecology could not be evaluated on 
univariate analysis or subsequent regression analysis. 
Thus, the effects of age and epidemiological factors on 
Cin (+) was investigated in 1649 women aged 20-29. 
Cin (+) lesions were observed in 61 (3.7%) women. 
Table 1 shows the epidemiological and clinical param-
eters of these 1649 women. Their median age was 26 
years, with 1126 women being aged 25-29. most of 
the women (94.6%) were not using any medically pre-
scribed contraceptive method.
epidemiological and clinical parameters in pa-
tients with cytologically or colposcopically normal or 
histologically diagnosed Cin (+) lesions are presented 
in Table 2. in comparison with women aged 20-24, 
those aged 25-29 were more likely to have Cin (+) 
(4.4% vs. 2.1%; p=0.019). The parameters of age, parity, 
smoking habit, use of oral contraceptive pills, and use 
of intrauterine device were included in the binomial 
logistic regression analysis. The only significant deter-
minant of Cin (+) was the increase in age, thus the 
occurrence of Cin (+) lesions increased 1.149 times 
each year in women aged 20-29 (Table 3).
Table 1. Epidemiological and clinical parameters of study 
population
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Discussion
This study analyzed cytology and histology out-
comes in the context of examining the effects of age 
and epidemiologic cofactors on Cin (+) in women 
aged 20-29. According to our results, while 12% of 
women had abnormal cytology results, hPv testing 
was positive in 24.9% of women aged 20-29. we also 
analyzed the effect of age on the occurrence of Cin 
(+) lesions in women aged 20-29 and found a one-year 
increase in age in these women to increase the occur-
rence of Cin (+) lesions 1.149 times.
Our study population was from the region of Tur-
key with one of the highest hPv rates4. in the 30-65 
age group, the hPv (+) rate is 4.4% nationally in Tur-
key but 6.2% in Antalya4. in our study group, 24.9% of 
women aged 20-29 were hPv (+). 
The reason for the high hPv (+) rate in our study 
as compared with data from the national hPv screen-
ing initiatives is the fact that the prevalence of hPv in 
our region is highest in Turkey and the study popula-
tion was of a younger age. indeed, persistent hPv in-
fection is mandatory for the development of Cin and 
cervical cancer5. hPv acquisition in a young female is 
believed to occur just after her becoming sexually ac-
tive, although the majority of this infection or early le-
sions become undetectable within one to two years6,7. 
high-risk hPv infection is relatively more common in 
females aged 20-29, with the highest incidence rate of 
43.4% observed among those aged 20-248. however, 
the incidence rate of cervical cancer is one of the lowest 
in this age group. This is because of the transient nature 
of hPv infection, and also because cervical cancer 
takes about 10 to 15 years after the onset of hPv in-
fection to develop. Thus, women with the disease diag-
nosed at 30-40 years of age may have a history of Cin 
in their twenties. in parallel to hPv prevalence, 12% of 
our study group had abnormal cytology results. in a 
Table 2. Epidemiological and clinical parameters in patients with cytologically or colposcopically normal or histologically 
diagnosed CIN (+) lesions


















































Cin (+) = cervical intraepithelial neoplasia or cancer; iQr = interquartile range; amann whitney U test; bPearson’s χ2-test; cfisher exact test
Table 3. Logistic regression analysis of factors predictive of CIN (+)
Coefficient Se wald df p Or 95% Ci for Orlower Upper
Age (years) 0.139 0.056 6.078 1 0.014 1.149 1.029 1.284
Se = standard error; df = degree of freedom; Or = odds ratio; Ci = confidence interval; Cin (+) = cervical intraepithelial neoplasia grade 
1 or higher; hosmer and lemeshow test value: 0.673
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comprehensive study by the Turkish Cervical Cancer 
and Cervical Cytology research group, the abnormal 
cytology prevalence rate in women of all ages was 
1.8%9. Additionally, a 9% to 19% prevalence rate of ab-
normal cytology in adolescents and young adults has 
been reported in previous studies10,11. These higher rates 
of cytologic abnormalities as compared with adult pop-
ulation can be explained by the increased hPv infec-
tion rate at these ages.
Previous studies have shown that age plays an im-
portant role in the development of Cin and cervical 
cancer12-14. in our study, we found that women aged 
25-29 in comparison with women aged 20-24 were 
more likely to have Cin (+) (4.4% vs. 2.1%; p=0.019). 
logistic regression analysis revealed that the only de-
terminant of Cin (+) was an increase in age. This 
means that the risk increase of Cin observed each 
year was valid for all ages in comparison with previous 
age. for example, women aged 27 were 1.149 times 
more likely to have Cin in comparison with women 
aged 26. Untreated Cin regresses, persists or progress-
es, and the rate of progression is higher in older wom-
en with Cin grades 2 and 312. Cin lesions require 
close observation or treatment. Treatment is complet-
ed via excisional procedures when Cin grades 2 or 3 
are diagnosed or when persistence of Cin grade 1 is 
observed. however, excisional procedures are related 
to adverse pregnancy outcomes; therefore, observation 
is another option for women planning to be pregnant 
in the future. with this strategy, unnecessary treat-
ment is not applied to the lesions to force regression 
and the side effects of treatment are prevented. in an 
observational cohort study from the United States 
(US), the annual incidence of abnormal cytology and 
Cin in women of all ages who undergo routine cervi-
cal cancer screening is reported to be about 5% and 
2.7%, respectively13. The same research revealed that 
the most common age group demonstrating abnormal 
cytology results and Cin were those aged 20-2913. 
Cin grade 1 was most commonly diagnosed in wom-
en aged 20-24 (5.1/1000), while Cin grades 2 and 3 
were most commonly diagnosed in women aged 25-29 
(4.1/1000)13. Similarly, Butorac et al. report that Cin 
was most commonly diagnosed in younger women and 
therefore surgical treatment is more commonly ap-
plied to women aged 25-35 in Croatia14. The rate of 
Cin in our study (36.9/1000) was high as compared 
with the previous research in women aged 20-29. we 
believe that our high rate of Cin recorded in this age 
group was due to the study population having the 
highest incidence rate of hPv in Turkey. The Cin in-
cidence rates are decreasing in societies that include 
hPv vaccine on the vaccination schedule15. Thus, 
there should be new screening guidelines for cervical 
cancer implemented in those societies, including the 
screening starting age. in contrast, hPv vaccine is not 
included at this time in the national vaccination sched-
ule in Turkey. despite this, Turkey has already desig-
nated screening to begin at the age of 30. Opportunis-
tic screening, which some younger women may un-
dergo, has been shown to have no benefit in preventing 
cervical cancer16. Thus, organized screening must be 
implemented if cervical cancer screening is suggested 
to be done in women aged 20-29. A similar effect of 
age increase on the prevalence of cervical premalignant 
lesions has also been documented for the progression 
of untreated Cin lesions via screening. Older patients 
have higher rates of progression and lower rates of 
 regression. Among women aged ≤24, 25-29, 30-34, 
35-39 and ≥40, progression rate was 10.6%, 13.5%, 
17.1%, 10.8% and 24.9%, respectively12. in the same 
study, it was shown that, independently of Cin grade 
and presence or absence of hPv lesions, the Cin le-
sion regression rate was reduced by 21% with each 
five-year age grouping12.
guidelines around the world present different rec-
ommendations on the starting age for cervical cancer 
screening. The world health Organization recom-
mends that screening be initiated at the age of 30, while 
most european (e.g., france, Belgium, ireland, italy, 
norway), Australian and Canadian guidelines recom-
mend the age of 25 years as when to initiate screen-
ing17-20. Separately, US guidelines recommend screen-
ing should start at 21 years of age21. Korean guidelines 
also recommend that screening should begin at 20 
years due to the country’s increased occurrence of high-
grade lesions and cervical carcinoma as compared with 
developed countries22. with these cut-off ages, many of 
these countries believe that the treatment of precancer-
ous lesions during pregnancy will be prevented. in par-
allel to the screening guidelines of the countries, screen-
ing programs differ as well, and the starting age for 
screening is a controversial issue. each country imple-
ments its cervical cancer screening policy depending 
upon its own cervical cancer statistics, internal dynam-
ics, and hPv (+) rate. moreover, hPv vaccine is in-
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cluded in the immunization schedule mostly depend-
ing on the economic power of the country.
Of note, makkonen et al. showed that the perfor-
mance of organized screening in finland, which offi-
cially introduces screening at 30 years, had no protec-
tive effect on cervical cancer among women younger 
than 25; however, when performed at age 25-29, it 
decreased the risk of cervical cancer by 48%16. in con-
trast, Andrae et al. showed that Sweden’s national cer-
vical cancer screening had a protective effect against 
cervical cancer among women aged 20-29. They point-
ed out that Sweden’s cervical cancer screening by cy-
tology approach reduced the rate of cervical cancer 
cases by about 58% in women aged 20-2923.
The aim of cervical cancer screening is to diagnose 
Cin before the onset of cancer. Thus, cervical cancer 
can be prevented by treatment of early lesions. The aim 
of studies analyzing the effectiveness of screening 
should not be focused on the detection rate of cancer. 
however, if we investigated the relationship between 
age and cervical cancer, we could see that the incidence 
of cervical cancer is related to the age of women. Ac-
cording to the international Agency for research on 
Cancer, the estimated cervical cancer rates at ages 20, 
25 and 30 years were about 0.30/100,000, 1.82/100,000 
and 2.80/100,000, respectively. Also, the increase in the 
rate of cervical cancer between age 20 and 25 was 
slightly higher than the increase recorded between age 
25 and 30 years24. in the United Kingdom (UK), cervi-
cal cancer incidence is highest in women aged 25-29 as 
compared with any other five-year period of a woman’s 
life. The incidence gradually decreases until age 60-64 
and then rises again25. The cervical cancer incidence 
rates per 100,000 women-years were 4.0 at age 20-24 
but 20.3 at age 25-2925. in comparison, in the US, the 
cervical cancer incidence rate per 100,000 women-years 
was 1.40 at age 20-24 but 5.94 at age 25-2926.
There are studies that address the roles of cofactors 
in the progression of cervical carcinoma in women of 
different age groups. in studies including adults older 
than 30, smoking, parity, and oral contraception and 
intrauterine device use were defined as cofactors for 
Cin and cervical cancer27-29. Among adolescents and 
young adults, no correlation was found between smok-
ing or use of oral contraceptives and Cin and hPv30. 
however, we found no relationship between these co-
factors and the occurrence of Cin in women aged 20-
29 either. Specifically, this may be due to the fact that 
temporary behavior of hPv in young women makes 
these cofactors ineffective in determining the progres-
sion of hPv to Cin and cervical cancer.
Study limitations
There were some limitations in our study that 
should be highlighted. Because it was a retrospective 
study, we were unable to question about the age of first 
sexual intercourse or the frequency and number of 
sexual partners of the women, which are the possible 
risk factors for hPv persistence in developing Cin 
and cervical cancer31. Another limitation was the lack 
of investigation of hPv subtypes, as a specific subtype 
may be more related to Cin development. it has been 
pointed out that the most carcinogenic subtypes (hPv 
subtypes 16 and 18) are most strongly related to high-
grade precancerous lesions and cervical cancer in the 
20-29 age group32. moreover, hPv subtypes 16 and 
18 cause Cin quicker and at younger ages, while other 
subtypes progress more slowly and cause Cin at older 
ages7. The final limitation of note was that the study 
population was from a single centre and the region 
(Antalya) displaying the upper limit of the hPv posi-
tivity in Turkey.
however, there also were significant advantages to 
this study. methodologically, the women included in 
the study met the ASCCP guidelines. Also, the entire 
study population included women aged <30 who were 
not screened by the national cervical cancer screening 
initiative in Turkey. in this manner, the study offers 
valuable information about the results of smear, hPv, 
and colposcopy in this unscreened population.
Conclusion
According to our findings and those of previous 
studies, age plays an important role in the develop-
ment of Cin (+). Thus, taking age in consideration is 
crucial in the diagnosis of Cin (+) on cancer screen-
ing. women aged 25-29 as compared to those aged 
20-24 are two times more likely to have Cin (+). Cin 
(+) lesions are 1.149 times more likely to develop with 
each one-year age progression. Although our study 
population did not represent the characteristics of the 
whole Turkey or the global population, our study pop-
ulation’s hPv positivity, abnormal cytology, and Cin 
rates were similar or higher than those of other popu-
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lations that have undergone such screening. Therefore, 
starting screening at age 25 instead of age 30 should be 
considered in our region, and further extensive studies 
are needed to decide on the optimal age to implement 
cervical cancer screening.
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Sažetak
UČinAK dOBi nA PrOBir rAKA vrATA mATerniCe KOd ženA U dOBi Od 20-29 gOdinA
H. A. Tuncer i S. Fırtına Tuncer
Zasad ne postoji konsenzus oko odgovarajuće dobi u kojoj treba započeti probir raka grlića maternice. Analizirali smo 
učinak dobi na nenormalne histološke ishode kod žena u dobi od 20-29 godina. retrospektivno su pregledani podaci žena u 
dobi od 20 do 29 godina kod kojih je probir oportunističkog raka grlića maternice s citologijom izvršen u razdoblju od 2014. 
do 2019. godine. na temelju rezultata citologije, rezultata ispitivanja humanog papilomavirusa, dobi i kliničke odluke bole-
snice se podvrgavaju kolposkopiji ili promatranju. Učinci dobi i drugih epidemioloških čimbenika na histološke dijagnoze 
cervikalne intraepitelijske neoplazije (Cin) ili karcinoma [Cin (+)] analizirani su univarijatnom i binomialnom logističkom 
regresijskom analizom. između 1649 žena Cin (+) lezije zabilježene su kod 61 (3,7%) žene. Pojava Cin (+) lezija povećava-
la se 1149 puta svake godine; stoga je vjerojatnije da su žene u dobi od 25 do 29 godina imale Cin (+) nego one u dobi od 
20-24 godine (4,4% prema 2,1%; p=0,019). Značajna odrednica Cin (+) bilo je povećanje dobi, tj. kod žena od 20-29 godi-
na. Uzimanje dobi u obzir presudno je u dijagnozi Cin (+) u probiru raka.
Ključne riječi: Rak grlića maternice; Dob probira; HPV; Citologija; Kolposkopija
